Rani Therapeutics Holdings Inc
Change company Symbol lookup
Select an option...
RANI Rani Therapeutics Holdings Inc
KIO KKR Income Opportunities Fund
BOXD Boxed Inc
TFPM Triple Flag Precious Metals Corp
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

Closing Price
$5.83
Day's Change
-0.07 (-1.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.17
Day's Low
5.80
Volume
(Light)
Volume:
12,964

10-day average volume:
29,949
12,964

Rani Therapeutics to Present at the Stifel Healthcare Conference

4:05 pm ET November 9, 2022 (Globe Newswire) Print
Rani Therapeutics to Present at the Stifel Healthcare ConferenceGlobeNewswireNovember 09, 2022

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022.

Talat Imran, Chief Executive Officer of Rani, is scheduled to present on Wednesday, November 16 at 9:45 AM EST / 6:45 AM PST.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com



Source: Rani Therapeutics





Primary Logo

comtex tracking

COMTEX_418491628/2010/2022-11-09T16:05:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.